FTC's New Rule Zeroes In On More Pharma Patent Deals

Law360, New York (August 13, 2012, 8:17 PM EDT) -- The Federal Trade Commission revealed plans Monday to broaden the types of exclusive pharmaceutical patent rights licenses that require antitrust approval, part of the agency's continuing drive to scrutinize agreements that could limit competition in the industry, attorneys say.

The FTC, in consultation with the U.S. Department of Justice, proposed amending its premerger notification rules governing what types of exclusive patent rights transfers require antitrust approval. The change, which is limited to the pharmaceutical industry, means that deals in which the patent owner hands over exclusive...
To view the full article, register now.